CellWell record HH-338049
Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clinical pharmacology and therapeutics ยท 1996
In plain language
Study of 20 volunteers demonstrated small intestine contributes substantially to first-pass metabolism of midazolam via CYP3A, with intestinal extraction similar to hepatic extraction.
- Evidence
- Established
- Design
- Randomized controlled trial
Cite this record: https://thecellwell.org/studies/HH-338049
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.